# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst John Hodulik upgrades AppLovin (NASDAQ:APP) from Neutral to Buy and raises the price target from $100 to $145.
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also rais...
BTIG analyst Clark Lampen maintains AppLovin (NASDAQ:APP) with a Buy and raises the price target from $114 to $150.
On CNBC's "Halftime Report Final Trades," Kari Firestone of Aureus Asset Management said Broadcom "is a good bu...
Wall Street witnessed a broad sell-off on Wednesday, except for the tech sector, as investor optimism over disinflation progres...